News tagged with emtricitabine
Related topics: hiv infection
Emtricitabine
Emtricitabine (FTC), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children.
Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread) under the brand name Truvada. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006 under the brand name Atripla.
For more information about Emtricitabine, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Early success of anti-HIV preventive oral drug regimen is promising, but questions remain
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure ...
Medicine & Health / HIV & AIDS
Mar 14, 2011 |
not rated yet |
0
Study examines HIV treatment response in men and women, finds overall similarities
A new landmark study, which demonstrated it is possible to recruit large numbers of women into a clinical trial evaluating treatments for HIV infection, found no significant gender-based differences in response to the anti-HIV ...
Medicine & Health / HIV & AIDS
Sep 20, 2010 |
not rated yet |
0
Clinical trial of antiretroviral-based HIV prevention strategies for women now under way
A new, large-scale clinical trial is examining whether antiretroviral medications normally used to treat HIV infection can also prevent HIV infection in women when applied as a vaginal gel or taken as oral tablets once daily.
Medicine & Health / HIV & AIDS
Sep 16, 2009 |
not rated yet |
0
